Must-read news from the week of November 14-18, 2022
A look at what the Contemporary Pediatrics® team covered this week.
Congenital hypopigmented macules on a healthy child
You are asked to evaluate an African American boy aged 4 years with a birthmark on his back and right arm. He is healthy with normal growth and development. What's the diagnosis?
How the FDA prevents drug shortages
At ACR Convergence 2022, Hyun Son, PharmD, discussed the role of the FDA’s Drug Shortage Staff in preventing and mitigating drug shortages.
VTAMA effective against pediatric atopic dermatitis
Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.
At ACR Convergence 2022, Amit Golding, MD, PhD, outlined drugs recently approved by the FDA, and discussed the requirements for biosimilars to meet approval.
Roflumilast cream safe, effective for atopic dermatitis in children 6 years and up
Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).
Juvenile idiopathic inflammatory myopathies after COVID-19 infection
In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.
Increased neurologic involvement from COVID-19 in 2021
In a recent study, investigators found that life-threatening neurologic conditions from severe acute COVID-19 were more frequent in 2021 than 2020.
Comparison of teen- and parent-reported estimates of social and emotional support, 2021 to 2022
July 23rd 2024The investigative team noted that teenagers with emotional and social support are better off to handle stressors such as biological and social transition, and are less likely to experience a variety of adverse physical and mental health outcomes.
